Bigmar Receives Swiss Approval to Formulate Metronidazole in IV Bags.

COLUMBUS, Ohio--(BUSINESS WIRE)--Dec. 13, 1999--

Company Also Announces Broader Plan to Formulate

Generic Oncology Drugs in IV Bags

Bigmar, Inc. (Nasdaq SmallCap: BGMR) today announced that it received approval from the Intercantonal Office for the Control of Medicine (IKS) in Switzerland to utilize IV bags as a drug delivery system for Metronidazole, an antibiotic used in the treatment of serious infections caused by anaerobic bacteria. This approval allows Bigmar to manufacture and market IV bags formulated with Metronidazole within Switzerland.

The Company also filed for approval from the IKS for the formulation of Nitroglycerin IV bags to be used in treating patients with heart disease. If approved by the IKS, management believes Bigmar will be the first company to manufacture and market Nitroglycerin in IV bags. Additionally, the Company plans to file for approval with the IKS to formulate Bupivacaine in infusion bags to be used in conjunction with patient-controlled pumps. Bupivacaine is a local anesthetic used in pain management.

These products will be produced by the Company's Bioren SA subsidiary in Switzerland for use in clinical settings. The Company expects to file Abbreviated New Drug Applications ("ANDA") with the Food and Drug Administration in the United States and also seek approvals from European regulatory authorities for these products during the first half of 2000. Shipments of the Nitroglycerin IV bags to Brazil have already commenced.

"The formulation of Metronidazole, Nitroglycerin and Bupivacaine in IV bags are the first steps towards what we believe is a much broader opportunity for Bigmar. By leveraging Bigmar Pharmaceuticals' expertise in utilizing Isolator Technology along with Bioren's infusion production capabilities, we seek to become the first company offering generic oncology (cancer) drugs in IV bags, which have been traditionally delivered in vials," stated John Tramontana, Chairman and Chief Executive Officer of Bigmar.

The procedure for formulating various dosages of drugs in IV bags is highly sophisticated. This is particularly true in the case of oncology drugs, which are very toxic and dangerous to handle. Approximately 30% of Bigmar's total R&D spending for the nine months ended September 30, 1999 was devoted to determining the stability of various drugs in IV bags, including the Company's generic oncology products.

Mr. Tramontana continued, "This is a unique innovation which we believe will be welcomed by healthcare workers in hospital and clinical settings, who will now be able to administer oncology drugs in an efficient, cost effective and ready to use package, completely avoiding the manipulation of toxic substances. In addition, they will no longer need to perform any dosage calculation, since Bigmar will formulate these drugs in varying but frequently prescribed dosages."

Mr. Tramontana concluded, "We believe that our Bigmar Pharmaceuticals SA and Bioren SA subsidiaries have the only facilities currently capable of formulating and mass producing various generic oncology drugs in IV bags."

Bigmar intends to formulate and market a number of generic oncology drugs in IV bags, including, Fluorouracil, Doxorubicin, Methotrexate, Dacarbazine, Carboplatin, Aclarubicin, Ganciclovir, Azathioprine, Cyclophosphamide, Ifosfamide, Melphalan, Vincristinsulphate, Cisplatin, Amsakrine, Etoposide, Vinblastin and Dactinomycin. In this regard, Bigmar plans to apply for ANDA approvals in the United States as well as various approvals from European regulatory authorities for the above-mentioned generic oncology drugs in IV bags during the first half of 2000. The Company has already received ANDA approvals in the United States for seven generic oncology drugs, including Fluorouracil and Methotrexate, but only in vials for injection.

BIGMAR, Inc.'s strategy is to supply world markets with a line of high quality, affordably priced pharmaceutical products with a focus on oncology. The Company has distribution rights to more than 20 generic oncological products and seven products approved by the FDA, which are manufactured in the Company's state-of-the-art facilities in Switzerland. The Company markets its products through partnerships with pharmaceutical distributors in Europe and the United States and focuses on off-patent oncological drugs. Additional information on Bigmar is available at www.bgmr.com.

Statements in this press release that are not strictly historical may be "forward-looking" statements which involve risks and uncertainties. No assurance can be given that the Company will successfully develop or commercialize its products, complete clinical trials, obtain regulatory approvals (or that any such approvals will be obtained on a timely basis) or be able to manufacture or successfully commercialize such products. Actual results may differ from those described in this press release due to risks and uncertainties that exist in the Company's operations, including, without limitation, the ability to obtain additional financing to continue operations when needed, a history of operating losses and accumulated deficits, the Company's reliance on collaborative relationships, and uncertainties related to clinical trials, the ability to obtain the appropriate regulatory approvals and market acceptance, as well as other risks detailed from time to time in publicly available filings with the Securities and Exchange Commission such as the Company's Annual Report on Form 10-K and its most recent Registration Statement on Form S-3 filed on December 8, 1999.

Actual results may differ materially from those currently anticipated as a result of such risks, and results for interim periods are not necessarily indicative of results to be expected for the full year. The Company undertakes no obligation to release publicly the results of any revision to these forward-looking statements to reflect events or circumstances arising after the date hereof. These statements are made pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995.